BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 8311114)

  • 1. c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung.
    Li ZH; Zheng J; Weiss LM; Shibata D
    Am J Pathol; 1994 Feb; 144(2):303-9. PubMed ID: 8311114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
    Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
    Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.
    Gealy R; Zhang L; Siegfried JM; Luketich JD; Keohavong P
    Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):297-302. PubMed ID: 10207632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
    Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
    Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of K-ras and p53 mutations in bronchoscopically obtained malignant and non-malignant tissue from patients with non-small cell lung cancer.
    Lang SM; Stratakis DF; Freudling A; Ebelt K; Oduncu F; Hautmann H; Huber RM
    Eur J Med Res; 2000 Aug; 5(8):341-6. PubMed ID: 10958767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
    Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
    Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy.
    Hongyo T; Buzard GS; Palli D; Weghorst CM; Amorosi A; Galli M; Caporaso NE; Fraumeni JF; Rice JM
    Cancer Res; 1995 Jun; 55(12):2665-72. PubMed ID: 7780983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.
    Hruban RH; van Mansfeld AD; Offerhaus GJ; van Weering DH; Allison DC; Goodman SN; Kensler TW; Bose KK; Cameron JL; Bos JL
    Am J Pathol; 1993 Aug; 143(2):545-54. PubMed ID: 8342602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features.
    Yamada T; Nakamori S; Ohzato H; Oshima S; Aoki T; Higaki N; Sugimoto K; Akagi K; Fujiwara Y; Nishisho I; Sakon M; Gotoh M; Monden M
    Clin Cancer Res; 1998 Jun; 4(6):1527-32. PubMed ID: 9626473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic alterations in K-ras and p53 cancer genes in lung neoplasms from Swiss (CD-1) male mice exposed transplacentally to AZT.
    Hong HH; Dunnick J; Herbert R; Devereux TR; Kim Y; Sills RC
    Environ Mol Mutagen; 2007; 48(3-4):299-306. PubMed ID: 16395694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
    Kern JA; Slebos RJ; Top B; Rodenhuis S; Lager D; Robinson RA; Weiner D; Schwartz DA
    J Clin Invest; 1994 Feb; 93(2):516-20. PubMed ID: 7906694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of K-ras mutation from malignant cells in sputum with mutant-allele specific amplification (MASA) method].
    Kimura S; Fukuchi K; Takeda S; Shin S; Saito D; Akamatsu S; Himeji Y; Chen GL; Watanabe H; Takagi Y
    Rinsho Byori; 1995 Jul; 43(7):718-23. PubMed ID: 7674546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of p53 gene mutations in the supernatant of bile for diagnosis of biliary tract carcinoma: comparison with K- ras mutation.
    Wang Y; Yamaguchi Y; Watanabe H; Ohtsubo K; Wakabayashi T; Sawabu N
    J Gastroenterol; 2002; 37(10):831-9. PubMed ID: 12424567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis.
    Sugio K; Ishida T; Yokoyama H; Inoue T; Sugimachi K; Sasazuki T
    Cancer Res; 1992 May; 52(10):2903-6. PubMed ID: 1581907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular genetics of malignant insulinoma.
    Pavelic K; Hrascan R; Kapitanovic S; Vranes Z; Cabrijan T; Spaventi S; Korsic M; Krizanac S; Li YQ; Stambrook P; Gluckman JL; Pavelic ZP
    Anticancer Res; 1996; 16(4A):1707-17. PubMed ID: 8712689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
    Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
    Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of epidermal growth factor receptor overexpression, K-ras point mutation and c-myc amplification in the carcinogenesis of non-small cell lung cancer.
    Sekine I; Takami S; Guang SG; Yokose T; Kodama T; Nishiwaki Y; Kinoshita M; Matsumoto H; Ogura T; Nagai K
    Oncol Rep; 1998; 5(2):351-4. PubMed ID: 9468555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant point mutation of tumor suppressor gene p53 and oncogene c-N-ras in malignant neuroendocrine pancreatic tumor.
    Hrasćan R; Pavelić K; Pavicić D; Krizanac S; Stajcer-Sittić V; Pecur L; Spaventi S; Klimpfinger M; Pavelić J
    Anticancer Res; 1996; 16(6B):3761-6. PubMed ID: 9042254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma.
    Mills NE; Fishman CL; Rom WN; Dubin N; Jacobson DR
    Cancer Res; 1995 Apr; 55(7):1444-7. PubMed ID: 7882350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines.
    Lehman TA; Bennett WP; Metcalf RA; Welsh JA; Ecker J; Modali RV; Ullrich S; Romano JW; Appella E; Testa JR
    Cancer Res; 1991 Aug; 51(15):4090-6. PubMed ID: 1855224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.